Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (AMN), Vanda (VNDA) and BioMarin Pharmaceutical (BMRN)

Tipranks - Wed Feb 18, 5:38AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AMN Healthcare Services (AMNResearch Report), Vanda (VNDAResearch Report) and BioMarin Pharmaceutical (BMRNResearch Report).

President's Day Sale - 70% Off

AMN Healthcare Services (AMN)

William Blair analyst Trevor Romeo maintained a Hold rating on AMN Healthcare Services today. The company’s shares closed last Friday at $16.25.

According to TipRanks.com, Romeo is a 1-star analyst with an average return of -0.9% and a 46.9% success rate. Romeo covers the Industrial Goods sector, focusing on stocks such as Republic Services, Waste Connections, and GFL Environmental. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AMN Healthcare Services with a $23.50 average price target.

See today’s best-performing stocks on TipRanks >>

Vanda (VNDA)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda, with a price target of $22.00. The company’s shares closed last Friday at $6.09.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 24.4% and a 57.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, Reviva Pharmaceuticals Holdings, and MoonLake Immunotherapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vanda with a $13.63 average price target, implying a 124.2% upside from current levels. In a report issued on February 12, Cantor Fitzgerald also maintained a Buy rating on the stock with a $11.00 price target.

BioMarin Pharmaceutical (BMRN)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Hold rating on BioMarin Pharmaceutical today and set a price target of $60.00. The company’s shares closed last Friday at $59.87.

According to TipRanks.com, Kapoor is a 4-star analyst with an average return of 7.5% and a 40.6% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Kyverna Therapeutics, Inc., Lexeo Therapeutics, Inc., and Cartesian Therapeutics. ;'>

BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $88.29.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.